Literature DB >> 10662591

Microsatellite instability and p53 mutations in hepatocellular carcinoma.

A Karachristos1, T Liloglou, J K Field, E Deligiorgi, E Kouskouni, D A Spandidos.   

Abstract

We have studied 27 hepatocellular carcinomas (HCCs) to identify possible relationships between microsatellite instability (MSI), p53 mutations, and HBV infection in hepatocarcinogenesis. MSI was assessed using 19 polymorphic markers and the poly(A) tract BAT-26. All coding regions of p53 were examined for mutations. Tumors were also examined for presence of hepatitis B virus (HBV) DNA sequences; 66.6% of the samples exhibit MSI in at least one microsatellite locus and 44% in two or three loci. None of the tumors examined showed alterations in BAT-26. Moreover, 73.3% of samples with indication of HBV infection showed instability in at least one marker. No association between MSI and pathological profile was found. Five (18.5%) samples harbored mutations in p53, three missense, and two insertions, all in exons 5 and 8 not previously reported. No mutations were detected in codon 249, which has been linked with dietary intake of aflatoxins. Our results support the hypothesis that HCC is a "low" MSI tumor. Only 1/5 samples with MSI in more than two markers harbored a mutation in p53. Although the number of samples is too small to support a statistical significance, this finding may indicate an inverse relationship between p53 mutations and MSI in HCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10662591     DOI: 10.1006/mcbr.1999.0170

Source DB:  PubMed          Journal:  Mol Cell Biol Res Commun        ISSN: 1522-4724


  8 in total

1.  Nuclear and mitochondrial DNA microsatellite instability in hepatocellular carcinoma in Chinese.

Authors:  Dian-Chun Fang; Li Fang; Rong-Quan Wang; Shi-Ming Yang
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Molecular genetics of hepatocellular neoplasia.

Authors:  Shilpa Jain; Shashideep Singhal; Peng Lee; Ruliang Xu
Journal:  Am J Transl Res       Date:  2010-01-23       Impact factor: 4.060

3.  Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China.

Authors:  Shu-Hui Zhang; Wen-Ming Cong; Zhi-Hong Xian; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

4.  Genomic instability of murine hepatocellular carcinomas with low and high metastatic capacities.

Authors:  Shu-Hui Zhang; Wen-Ming Cong; Jing-Quan Shi; Hong Wei
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

Review 5.  Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Authors:  Margherita Ratti; Andrea Lampis; Jens C Hahne; Rodolfo Passalacqua; Nicola Valeri
Journal:  Cell Mol Life Sci       Date:  2018-09-01       Impact factor: 9.261

Review 6.  Involvement of DNA damage response pathways in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Chien-Wei Chang; Ren-Jie Wei; Yow-Ling Shiue; Shen-Nien Wang; Yao-Tsung Yeh
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

Review 7.  Hypermutation and microsatellite instability in gastrointestinal cancers.

Authors:  Kizuki Yuza; Masayuki Nagahashi; Satoshi Watanabe; Kazuaki Takabe; Toshifumi Wakai
Journal:  Oncotarget       Date:  2017-12-01

8.  The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.

Authors:  Kaoru Tsuchiya; Masayuki Kurosaki; Azusa Sakamoto; Hiroyuki Marusawa; Yuji Kojima; Chitomi Hasebe; Hirotaka Arai; Kouji Joko; Masahiko Kondo; Keiji Tsuji; Tetsuro Sohda; Hiroyuki Kimura; Chikara Ogawa; Yasushi Uchida; Shuichi Wada; Haruhiko Kobashi; Koichiro Furuta; Masaya Shigeno; Atsunori Kusakabe; Takehiro Akahane; Ryoichi Narita; Hideo Yoshida; Akeri Mitsuda; Yasushi Ide; Tomomichi Matsushita; Namiki Izumi
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.